跳至主要内容
临床试验/NCT07483645
NCT07483645进行中(未招募)不适用

Effectiveness and Acceptability of a Liposomal Iron Supplement With Vitamin C and Fiber (LISEFEX®): Observational, Descriptive, Prospective, Longitudinal, Multicenter Study in Mexican Subjects Diagnosed With Mild to Moderate Iron Deficiency Anemia.

Carnot Laboratories1 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2025年5月6日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
74
试验地点
1
主要终点
Hemoglobin level

研究概览

简要总结

Observational, descriptive, prospective, longitudinal, multicenter, non-interventionist and multicentric study in Mexican subjects diagnosed with mild to moderate iron deficiency anemia (ADH). Main objective:To evaluate the effectiveness and acceptability of LISEFEX® supplement in patients with mild to moderate iron deficiency anemia.Design The minimal risk study, no therapeutic interventions were carried out by the research team. The indication for supplementation with LISEFEX® was made by the treating physician as part of standard clinical practice, while the study was limited to systematic collection of clinical and laboratory information during participant follow-up.

详细描述

The primary objective of this study was to describe the evolution of hemoglobin levels from baseline to weeks 1, 2, 4, 8 and 12 of supplementation with LISEFEX®.

Secondary objectives, the aim is to describe various hematological, biochemical and safety parameters throughout the follow-up period in both cohorts. In particular, the percentage of reticulocytes was evaluated basal and in weeks 2, 4, 8 and 12 of supplementation. Also, the values of mean corpuscular volume (MCV), mean corpuscular hemoglobin (HCM) and corpuscular hemoglobin concentration were described mean (CHCM) baseline and follow-up weeks 1, 2, 4, 8, and 12.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of iron deficiency anemia.
  • Candidates over 18 years.
  • Candidates with Informed Consent signed.
  • Candidates who have been instructed by their treating physician to start treatment with LISEFEX
  • Candidates with the ability to swallow substances orally.

排除标准

  • Pregnancy or breastfeeding.
  • Having received any treatment in the last 3 months for iron deficiency anemia.

结局指标

主要结局

Hemoglobin level

时间窗: 12 weeks

次要结局

未报告次要终点

研究者

发起方
Carnot Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验